新型尿液生物标志物检测在前列腺癌诊断中的准确性：一项系统评价和网状Meta分析
Accuracy of novel urinary biomarker tests in the diagnosis of prostate cancer: A systematic review and network meta-analysis.
作者信息
Wang Leibo, He Wei, Shi Guanyu, Zhao Guoqiang, Cen Zhuangding, Xu Feng, Tian Wu, Zhao Xin, Mo Chishou
机构信息
Surgery, Guizhou Orthopaedic Hospital, Guiyang, Guizhou, China.
Department of Urology, Fenggang County People's Hospital, Zunyi, Guizhou, China.
出版信息
Front Oncol. 2022 Nov 15;12:1048876. doi: 10.3389/fonc.2022.1048876. eCollection 2022.
OBJECTIVE
The purpose of this study was to conduct a network meta-analysis comparing the diagnostic value of different urinary markers for prostate cancer.
METHODS
As of June 2022, the literature was retrieved by searching Pubmed, EMBASE, Web of Science databases and other databases. The methodological quality of included studies was assessed using the Cochrane Collaboration's risk of bias tool, and publication bias was assessed using funnel plots. The surface under the cumulative ranking curve (SUCRA) values was used to determine the most effective diagnostic method and the data were analyzed accordingly using data analysis software.
RESULTS
A total of 16 articles was included including 9952 patients. The ranking results of network meta-analysis showed that the diagnostic performance of the four urine markers Selectmdx, MIPS, PCA3 and EPI was better than that of PSA. Among them, the specificity, positive predictive value and diagnostic accuracy of Selectmdx ranked first in the SUCRA ranking (SUCRA values: 85.2%, 88.3%, 97.1%), and the sensitivity ranked second in the SUCRA ranking (SUCRA value: 54.4%), and the negative predictive value ranked fourth in SUCRA (SUCRA value: 51.6%). The most sensitive screening tool was MIPS (SUCRA value: 67.1%), and it was also the second screening tool ranked higher in specificity, positive predictive value, negative predictive value and diagnostic accuracy (SUCRA value: 56.5%, respectively)., 57.1%, 67.9%, 74.3%). The high negative predictive value SUCRA ranking is EPI (SUCRA value: 68.0%), its sensitivity ranks third (SUCRA value: 45.6%), and its specificity, positive predictive value and diagnostic accuracy are ranked fourth (SUCRA values are: 45%, 38.2%, 35.8%).
CONCLUSION
According to the network ranking diagram, we finally concluded that Selectmdx and MIPS can be used as the most suitable urine markers for prostate cancer screening and diagnosis. To further explore the diagnostic value of different urinary markers in the screening of PCa patients.
SYSTEMATIC REVIEW REGISTRATION
https://inplasy.com/, identifier INPLASY202290094.
目的
本研究旨在进行一项网状Meta分析，比较不同尿液标志物对前列腺癌的诊断价值。
方法
截至2022年6月，通过检索Pubmed、EMBASE、Web of Science数据库及其他数据库获取文献。采用Cochrane协作网偏倚风险工具评估纳入研究的方法学质量，采用漏斗图评估发表偏倚。使用累积排序曲线下面积（SUCRA）值确定最有效的诊断方法，并使用数据分析软件进行相应分析。
结果
共纳入16篇文章，涉及9952例患者。网状Meta分析的排序结果显示，四种尿液标志物Selectmdx、MIPS、PCA3和EPI的诊断性能优于前列腺特异性抗原（PSA）。其中，Selectmdx的特异性、阳性预测值和诊断准确性在SUCRA排序中排名第一（SUCRA值分别为：85.2%、88.3%、97.1%），敏感性在SUCRA排序中排名第二（SUCRA值：54.4%），阴性预测值在SUCRA中排名第四（SUCRA值：51.6%）。最敏感的筛查工具是MIPS（SUCRA值：67.1%），其在特异性、阳性预测值、阴性预测值和诊断准确性方面也分别是排名较高的第二种筛查工具（SUCRA值分别为：56.5%、57.1%、67.9%、74.3%）。阴性预测值SUCRA排名较高的是EPI（SUCRA值：68.0%），其敏感性排名第三（SUCRA值：45.6%），其特异性、阳性预测值和诊断准确性排名第四（SUCRA值分别为：45%、38.2%、35.8%）。
结论
根据网状排序图，我们最终得出结论，Selectmdx和MIPS可作为前列腺癌筛查和诊断最合适的尿液标志物。进一步探索不同尿液标志物在前列腺癌患者筛查中的诊断价值。
系统评价注册
Zotero 插件